Phase 2 Trial of ZEN003694 in Squamous Cell Lung Cancer Patients Harboring NSD3 Amplification
Memorial Sloan Kettering Cancer Center
Summary
The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene. ZEN003694 is a type of drug called a BET inhibitor. Researchers think ZEN003694 may help here because the drug works by blocking a group of proteins called bromodomain and extra-terminal (BET) proteins, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of the cancer.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Histologically-confirmed squamous cell lung cancer * Recurrent or metastatic disease * Patients with previously treated asymptomatic brain metastases requiring no more than 10mg prednisone (or equivalent) are allowed. Patients with asymptomatic brain metastases ≤ 1cm not requiring more than 10mg prednisone (or equivalent) are allowed. * Received prior first-line therapy: platinum-based chemotherapy and immunotherapy, given either concurrently or sequentially * Eastern Cooperative Oncology Group (ECOG) PS 0-2 * Evidence of NSD3 gain or amplification by NGS, including but…
Interventions
- DrugZEN003694
ZEN003694 60mg po qd on a 5 days on 2 days off schedule in an every 21-day cycle
Locations (7)
- Memorial Sloan Kettering at Basking Ridge Limited Protocol ActivitiesBasking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities)Montvale, New Jersey
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities )Commack, New York
- Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, New York